American Journal of Hospice and Palliative Medicine®

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Click here to sign up for SAGE Journal Email Alerts today!

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Carter, G. T.
Right arrow Articles by Weiss, M. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Carter, G. T.
Right arrow Articles by Weiss, M. D.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
American Journal of Hospice and Palliative Medicine®, Vol. 23, No. 5, 412-416 (2006)
DOI: 10.1177/1049909106292169

Modafinil Reduces Fatigue in Charcot-Marie-Tooth Disease Type 1A: A Case Series

Gregory T. Carter, MD

Department of Rehabilitation Medicine, University of Washington School of Medicine, Seattle, Washington, gtcarter{at}u.washington.edu

Jay J. Han, MD

Departments of Physical Medicine and Rehabilitation, University of California, Davis School of Medicine, Davis, California

Angeli Mayadev, MD

Department of Rehabilitation Medicine, University of Washington School of Medicine, Seattle, Washington

Michael D. Weiss, MD

Department of Neurology, University of Washington School of Medicine, Seattle, Washington

Charcot-Marie-Tooth disease, the most common hereditary motor and sensory neuropathy, is a slowly progressive disorder characterized by diffuse muscle weakness and prominent distal atrophy that predominantly involves the intrinsic muscles of the feet and the peroneal muscles. It results in marked reduction in functional aerobic capacity during exercise and fatigue is commonly reported. To date, no pharmacologic treatment has been shown to be effective for treating fatigue in Charcot-Marie-Tooth. Modafinil is used to treat the symptoms of fatigue and excessive daytime sleepiness in narcolepsy. However, fatigue and subsequent excessive daytime sleepiness secondary to fatigue are common symptoms in many neurologic disorders. Prior reports on patients with myotonic muscular dystrophy, multiple sclerosis, Parkinson’s disease, and amyotrophic lateral sclerosis, have shown beneficial effects of modafinil in treating fatigue. We report 4 patients with genetically confirmed Charcot-Marie-Tooth disease who had significant fatigue that was almost completely relieved by modafinil.

Key Words: Charcot-Marie-Tooth disease • hereditary motor and sensory neuropathy • fatigue


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?